Need to keep on prime of the science and politics driving biotech at present? Join to get our biotech e-newsletter in your inbox.
The FDA’s shock refusal to even assessment Moderna’s mRNA flu vaccine is sending a chill by biotech: Corporations are brazenly questioning whether or not the regulatory goalposts are shifting underneath the Trump administration.
Programming notice: This text is taking a vacation on Monday however can be again in your inbox on Tuesday.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
